Progressive Pericardial Effusions (PEF) in Patients With Pulmonary Arterial Hypertension (PAH) Taking Sotatercept—Association With Pre-Existing Pericardial Effusion

26 November 2025

Hilamber Subba, Tapan H. Mehta, John Gilboy, Jacob Gelman, Rachel Cutting, Kellie Ramsdell, Heidi Roy, Joel A. Wirth

https://doi.org/10.1002/pul2.70215 

 

Abstract

Pericardial effusion (PEF) in PAH may be a marker of worsening disease or associated with autoimmune conditions. Sotatercept was not initially reported as associated with the development or progression of PEF. We describe PAH patients taking sotatercept who were found to have new or worsening PEF and examine associated comorbidities.

Read the full research letter

Share:

More from Pulmonary Circulation

Show more details

A collection of up-to-date abstracts from our premier, international, peer-reviewed, medical research journal dedicated exclusively to pulmonary circulation and pulmonary vascular disease. 

Initial Experience of Multipurpose Mechanical Aspiration System for Acute High-Risk Pulmonary Embolism: A Prospective Multi-Center Case Series
Why Is Pulmonary Endarterectomy Underused in Japan? Epidemiology, Genetics, and a Practical Operability Framework
Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension
Altered Arginine Metabolism in Children Undergoing Fontan Palliation: A Prospective Cohort Study
Circulating Pin1 Levels in Patients With Chronic Thromboembolic Pulmonary Hypertension: A Case-Control Study
Macitentan Plus Tadalafil Single-Tablet Combination Therapy in Chinese Patients With Pulmonary Arterial Hypertension: A Subgroup Analysis of the A DUE Study
Substance P Promotes Pulmonary Hypertension by Inducing Fibulin-2 Methylation to Regulate β-Catenin
Phenotypic Analysis of Pulmonary Hypertension Associated With Low Diffusion Capacity and Preserved Lung Function
Chronic Dyspnea and Residual Pulmonary Vascular Sequelae After COVID-19 Pulmonary Embolism: A Retrospective Analysis
American Lung Association Pulmonary Hypertension Roundtable: Executive Summary
Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories
Real-World Comparison of Patients With PH-ILD Initiating Inhaled Treprostinil Versus Patients Who Remain Untreated
Prevalence of Pulmonary Arterial Thrombosis in Adults With Eisenmenger Syndrome
Identification and Validation of Potential Diagnostic Biomarkers for Pulmonary Arterial Hypertension Based on Gene Expression Profiling
Incremental Burden of Pulmonary Hypertension Among Patients With Interstitial Lung Disease in the Real-World Setting

Other materials on this topic

20 November 2025

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a chronic, progressive, and ultimately life-threatening disease characterized by vascular remodeling and increasing pulmonary vascular resistance. Despite significant advances in diagnostic tools and therapeutic strategies, clinical intervention often begins only when patients become symptomatic—typically at New York Heart Association (NYHA) functional class II or higher.

Pulmonary Circulation